 Joseph Margolick
Concepts (139)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 12 | 2025 | 353 | 2.960 |
Why?
| | Wounds and Injuries | 2 | 2024 | 280 | 1.300 |
Why?
| | Acquired Immunodeficiency Syndrome | 3 | 2022 | 52 | 1.220 |
Why?
| | Thyroidectomy | 2 | 2018 | 59 | 1.170 |
Why?
| | Sleep Apnea Syndromes | 2 | 2024 | 29 | 1.060 |
Why?
| | Homosexuality, Male | 2 | 2024 | 51 | 0.970 |
Why?
| | Cytomegalovirus | 1 | 2024 | 27 | 0.950 |
Why?
| | Cytomegalovirus Infections | 1 | 2024 | 34 | 0.940 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 123 | 0.890 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2024 | 159 | 0.850 |
Why?
| | Calcium | 1 | 2024 | 398 | 0.800 |
Why?
| | C-Reactive Protein | 1 | 2022 | 143 | 0.760 |
Why?
| | Postoperative Complications | 2 | 2018 | 1000 | 0.740 |
Why?
| | International Educational Exchange | 1 | 2020 | 7 | 0.720 |
Why?
| | Disaster Planning | 1 | 2020 | 37 | 0.690 |
Why?
| | Critical Care | 2 | 2024 | 213 | 0.670 |
Why?
| | Patient Readmission | 2 | 2018 | 221 | 0.660 |
Why?
| | Clinical Competence | 1 | 2022 | 393 | 0.640 |
Why?
| | Cohort Studies | 7 | 2024 | 1400 | 0.640 |
Why?
| | General Surgery | 1 | 2020 | 106 | 0.640 |
Why?
| | Inflammation | 1 | 2022 | 602 | 0.610 |
Why?
| | Parathyroidectomy | 1 | 2018 | 46 | 0.590 |
Why?
| | Venous Thromboembolism | 1 | 2018 | 67 | 0.570 |
Why?
| | Emergency Service, Hospital | 2 | 2018 | 487 | 0.570 |
Why?
| | Anticoagulants | 1 | 2018 | 253 | 0.500 |
Why?
| | Internship and Residency | 1 | 2020 | 442 | 0.480 |
Why?
| | Risk Assessment | 1 | 2018 | 1253 | 0.430 |
Why?
| | Humans | 25 | 2025 | 49863 | 0.420 |
Why?
| | Male | 15 | 2025 | 25439 | 0.380 |
Why?
| | Coronary Stenosis | 2 | 2022 | 99 | 0.370 |
Why?
| | Middle Aged | 11 | 2025 | 12258 | 0.370 |
Why?
| | Adult | 8 | 2025 | 13325 | 0.300 |
Why?
| | Reoperation | 2 | 2018 | 451 | 0.260 |
Why?
| | Aged | 7 | 2024 | 9434 | 0.250 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2024 | 3 | 0.240 |
Why?
| | Open Reading Frames | 1 | 2024 | 54 | 0.240 |
Why?
| | Polysomnography | 1 | 2024 | 70 | 0.230 |
Why?
| | Hypocalcemia | 1 | 2024 | 12 | 0.230 |
Why?
| | Proteome | 2 | 2025 | 153 | 0.230 |
Why?
| | Retrospective Studies | 3 | 2024 | 6106 | 0.230 |
Why?
| | Blood Coagulation Disorders | 1 | 2024 | 37 | 0.220 |
Why?
| | Oximetry | 1 | 2024 | 65 | 0.220 |
Why?
| | Blood Transfusion | 1 | 2024 | 125 | 0.210 |
Why?
| | Central Venous Catheters | 1 | 2023 | 25 | 0.210 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2023 | 58 | 0.210 |
Why?
| | Aging | 2 | 2024 | 669 | 0.210 |
Why?
| | Intensive Care Units | 1 | 2024 | 223 | 0.210 |
Why?
| | Female | 8 | 2025 | 26520 | 0.210 |
Why?
| | Canada | 2 | 2020 | 103 | 0.200 |
Why?
| | Proteomics | 1 | 2025 | 293 | 0.200 |
Why?
| | Emergency Medical Services | 1 | 2023 | 110 | 0.200 |
Why?
| | Cardiac Tamponade | 1 | 2022 | 27 | 0.200 |
Why?
| | Feedback | 1 | 2022 | 52 | 0.200 |
Why?
| | Chemotaxis | 1 | 2021 | 22 | 0.200 |
Why?
| | Semen | 1 | 2021 | 21 | 0.200 |
Why?
| | Pericardial Effusion | 1 | 2022 | 39 | 0.200 |
Why?
| | HIV-1 | 1 | 2021 | 53 | 0.190 |
Why?
| | Problem-Based Learning | 1 | 2022 | 47 | 0.190 |
Why?
| | RNA | 1 | 2022 | 167 | 0.190 |
Why?
| | Cytokines | 1 | 2024 | 612 | 0.190 |
Why?
| | Cardiomyopathies | 1 | 2022 | 114 | 0.190 |
Why?
| | International Cooperation | 1 | 2021 | 44 | 0.190 |
Why?
| | Prevalence | 2 | 2022 | 951 | 0.190 |
Why?
| | Monocytes | 1 | 2021 | 131 | 0.190 |
Why?
| | British Columbia | 1 | 2020 | 4 | 0.180 |
Why?
| | Red Cross | 1 | 2020 | 4 | 0.180 |
Why?
| | Mexico | 1 | 2020 | 35 | 0.180 |
Why?
| | Surgical Procedures, Operative | 1 | 2021 | 66 | 0.180 |
Why?
| | Cocaine | 1 | 2021 | 168 | 0.180 |
Why?
| | Oxygen | 1 | 2022 | 324 | 0.170 |
Why?
| | Quality of Life | 2 | 2022 | 837 | 0.170 |
Why?
| | Atherosclerosis | 1 | 2022 | 209 | 0.170 |
Why?
| | Risk Factors | 2 | 2018 | 3597 | 0.170 |
Why?
| | Heart Failure | 1 | 2025 | 505 | 0.160 |
Why?
| | Universities | 1 | 2020 | 169 | 0.160 |
Why?
| | Curriculum | 1 | 2022 | 397 | 0.160 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 553 | 0.160 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 15 | 0.160 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 271 | 0.150 |
Why?
| | MicroRNAs | 1 | 2021 | 349 | 0.150 |
Why?
| | Rectum | 2 | 2013 | 52 | 0.130 |
Why?
| | Young Adult | 2 | 2022 | 4013 | 0.130 |
Why?
| | Length of Stay | 1 | 2018 | 623 | 0.120 |
Why?
| | Heart Atria | 2 | 2025 | 57 | 0.110 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2013 | 4 | 0.110 |
Why?
| | Ciprofloxacin | 1 | 2013 | 21 | 0.110 |
Why?
| | Prospective Studies | 4 | 2024 | 2341 | 0.110 |
Why?
| | Escherichia coli Infections | 1 | 2013 | 29 | 0.110 |
Why?
| | Povidone-Iodine | 1 | 2012 | 3 | 0.110 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 46 | 0.100 |
Why?
| | Drug Resistance, Bacterial | 1 | 2013 | 72 | 0.100 |
Why?
| | Antibiotic Prophylaxis | 1 | 2013 | 61 | 0.100 |
Why?
| | Image-Guided Biopsy | 1 | 2012 | 33 | 0.100 |
Why?
| | Anti-Infective Agents, Local | 1 | 2012 | 24 | 0.100 |
Why?
| | Feces | 1 | 2013 | 131 | 0.100 |
Why?
| | Prostate | 1 | 2012 | 117 | 0.100 |
Why?
| | Bacterial Infections | 1 | 2012 | 93 | 0.100 |
Why?
| | Escherichia coli | 1 | 2013 | 189 | 0.100 |
Why?
| | Preoperative Care | 1 | 2012 | 167 | 0.090 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 390 | 0.080 |
Why?
| | Loneliness | 1 | 2024 | 12 | 0.060 |
Why?
| | Carbon Monoxide | 1 | 2024 | 40 | 0.060 |
Why?
| | Sarcopenia | 1 | 2024 | 89 | 0.060 |
Why?
| | Infusions, Intraosseous | 1 | 2023 | 5 | 0.050 |
Why?
| | Chromosomes, Human, Y | 1 | 2023 | 3 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2024 | 147 | 0.050 |
Why?
| | Mosaicism | 1 | 2023 | 18 | 0.050 |
Why?
| | Injections, Intravenous | 1 | 2023 | 141 | 0.050 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2022 | 1 | 0.050 |
Why?
| | Pain Management | 1 | 2024 | 164 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2024 | 577 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2023 | 212 | 0.050 |
Why?
| | Resuscitation | 1 | 2023 | 72 | 0.050 |
Why?
| | Coroners and Medical Examiners | 1 | 2022 | 8 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2022 | 29 | 0.050 |
Why?
| | Viremia | 1 | 2022 | 22 | 0.050 |
Why?
| | Autopsy | 1 | 2022 | 47 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2022 | 95 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2022 | 113 | 0.050 |
Why?
| | Biomedical Research | 1 | 2024 | 239 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2022 | 210 | 0.050 |
Why?
| | Respiration, Artificial | 1 | 2024 | 290 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2022 | 265 | 0.050 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 107 | 0.050 |
Why?
| | Developing Countries | 1 | 2021 | 54 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2021 | 3132 | 0.050 |
Why?
| | Base Sequence | 1 | 2021 | 644 | 0.050 |
Why?
| | Coronary Angiography | 1 | 2022 | 353 | 0.040 |
Why?
| | Comorbidity | 1 | 2021 | 607 | 0.040 |
Why?
| | Hypertension | 1 | 2024 | 531 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2024 | 480 | 0.040 |
Why?
| | Pandemics | 1 | 2022 | 566 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2025 | 1526 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 1568 | 0.040 |
Why?
| | United States | 1 | 2024 | 4870 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2013 | 553 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2012 | 137 | 0.020 |
Why?
| | Adolescent | 1 | 2021 | 6392 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2013 | 5165 | 0.010 |
Why?
|
|
Margolick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|